全部 标题 作者 关键词 摘要
DOI: 10.3971/j.issn.1000-8578.2018.17.0975
Keywords: A Predictor of Risk and Prognosis of Breast Cancer,Tanshinone ⅡA Enhances Chemosensitivity of Breast Cancer Cells to Doxorubicin and Related Mechanism,In Situ Hybridization Status of 568 Cases of HER2 Equivocal Breast Cancer,Safety and Efficacy of Percutaneous Vertebroplasty on Spinal Metastases with Incomplete Posterior Wall,Progress of Molecular Imaging in Diagnosis of HER2 Positive Tumors,Apatinib Suppresses Proliferation and Induced Apoptosis of Human Breast Cancer Cell Line MDA-MB-231 Through Glycolytic Inhibition,Progress of Whole Exon Sequencing in Pathogenesis and Diagnosis of Breast Cancer,Feedback Activation of STAT3 Confers Resistance of HER2-positive Breast Cancer Cells to Lapatinib,Influence of NRP-1 Monoclonal Antibody on Growth of Breast Cancer Xenografts in Nude Mouse
Full-Text Cite this paper Add to My Lib
摘要 目的 探讨HER2阳性乳腺癌患者应用曲妥珠单抗治疗的心脏安全性。方法 185例HER2阳性乳腺癌患者接受每3周一次的曲妥珠单抗治疗，首次以负荷剂量8 mg/kg给药，此后每3周给予6 mg/kg静脉滴注，接受治疗4~36周期，观察其心脏安全性。结果 接受曲妥珠单抗治疗的HER2阳性乳腺癌患者中位治疗周期数为17个（4~36个），88例（47.6%）出现LVEF下降、74例（40.0%）出现瓣膜反流（新增+加重）、16例（8.0%）出现左室舒张功能下降。发生心脏毒性88例（47.6%），其中Ⅰ级心脏毒性83例、Ⅱ级心脏毒性5例，未见Ⅲ级心脏毒性发生。结论 曲妥珠单抗对HER2阳性乳腺癌患者心脏功能有一定影响，总体安全性良好。但是，在治疗中仍需注意评估与监测
Full-Text
Contact Us
service@oalib.com
QQ:3279437679
WhatsApp +8615387084133
